Rapid completion of enrollment in the DIAMOND (DIAbetic Macular edema patients ON a Drop) program, consisting of two (2) Phase 3, double-masked, randomized, multi-center trials to evaluate the ...

Register for the event here. To learn more about the Phase 3 DIAMOND trials, please visit diamondtrial.com. About OCS-01 eye drops and OPTIREACH® technology Leveraging Oculis’ proprietary ...

Register for the event here. To learn more about the Phase 3 DIAMOND trials, please visit diamondtrial.com. -ENDS- Leveraging Oculis' proprietary technology, OCS-01 is an OPTIREACH® formulation ...

today announced that it has completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME, designed as pivotal registration studies to support global marketing ...

Register for the event here . To learn more about the Phase 3 DIAMOND trials, please visit . Leveraging Oculis' proprietary technology, OCS-01 is an OPTIREACH® formulation of high concentration ...